ANTIENDOTHELIAL ANTIBODIES IN THE SERA OF CANCER-PATIENTS - A POSSIBLE INDICATOR OF TREATMENT-INDUCED TISSUE-DAMAGE

被引:0
|
作者
KUMAR, S [1 ]
CAIRNDUFF, F [1 ]
WANG, M [1 ]
PYE, D [1 ]
KUMAR, P [1 ]
ALLAN, E [1 ]
HUNTER, RD [1 ]
机构
[1] MANCHESTER POLYTECH, MANCHESTER M20 9BX, ENGLAND
来源
CANCER JOURNAL - FRANCE | 1992年 / 5卷 / 05期
关键词
ANTIENDOTHELIAL ANTIBODY; RADIOTHERAPY AND AUTOANTIBODY; CHEMOTHERAPY AND AUTOANTIBODY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background - Radiation can cause severe injury to the vasculature in patients receiving radiotherapy. However, no assay is available which can either detect or predict such damage. In several diseases where damage to the vasculature occurs, the presence of antibodies to endothelial cells (AEA) has been noted. Methods - The incidence of AEA in the sera of normal individuals and cancer patients who have been treated by radiotherapy, chemotherapy, or radiotherapy and chemotherapy in combination, was investigated by an indirect immunofluorescence technique against human umbilical vein endothelial cells. Results - The incidence of AEA in the sera of 57 untreated cancer patients and 147 normal individuals was significantly lower than in 277 treated cancer patients (p=0.001, Pearson's Chi-squared test). The incidence of AEA was higher in cancer patients with disseminated disease than in patients with localised disease. Furthermore, 8/28 patients with AEA but only 20/242 without AEA, died during the course of this study (p=0.01, Pearson's Chi-squared test). Discussion - The higher incidence of AEA in the sera of treated cancer patients was predictable. To assess the clinical usefulness of these findings, longer-term follow-up studies need to be undertaken.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 50 条
  • [31] PATHOGENESIS AND DEFEROXAMINE TREATMENT OF ISCHEMIA-INDUCED TISSUE-DAMAGE IN LATISSIMUS DORSI MYOCUTANEOUS (LDM) FLAPS IN PIGS
    MORRIS, SF
    LOFCHY, NM
    PANG, CY
    FASEB JOURNAL, 1988, 2 (04): : A820 - A820
  • [32] Optimal Management of Cancer Treatment-Induced Bone Loss Considerations for Elderly Patients
    Tipples, Karen
    Robinson, Anne
    DRUGS & AGING, 2011, 28 (11) : 867 - 883
  • [33] Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
    Peddi, Parvin F.
    Fasching, Peter A.
    Liu, Duan
    Quinaux, Emmanuel
    Robert, Nicholas J.
    Valero, Vicente
    Crown, John
    Falkson, Carla
    Brufsky, Adam
    Cunningham, Julie M.
    Weinshilboum, Richard M.
    Pienkowski, Tadeusz
    Eiermann, Wolfgang
    Martin, Miguel
    Bee, Valerie
    Wang, Xiaoyan
    Wang, Liewei
    Yang, Eric
    Slamon, Dennis J.
    Hurvitz, Sara A.
    CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1854 - 1862
  • [34] EVIDENCE OF DRUG-METABOLISM BY MACROPHAGES - POSSIBLE ROLE OF MACROPHAGES IN THE PATHOGENESIS OF DRUG-INDUCED TISSUE-DAMAGE AND IN THE ACTIVATION OF ENVIRONMENTAL PROCARCINOGENS
    WICKRAMASINGHE, SN
    CLINICAL AND LABORATORY HAEMATOLOGY, 1987, 9 (03): : 271 - 280
  • [35] POTENTIAL USE OF SPECIFIC HUMAN AND CHICKEN ANTIBODIES FOR DETECTION OF HANGANUTZIU-DEICHER ANTIGEN(S) IN SERA OF CANCER-PATIENTS
    MUKURIA, CJ
    NOGUCHI, A
    SUZUKI, E
    NAIKI, M
    JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY, 1994, 47 (5-6): : 253 - 264
  • [36] ANTIBODIES TO ADENO-ASSOCIATED SATELLITE VIRUS AND HERPES-SIMPLEX IN SERA FROM CANCER-PATIENTS AND NORMAL ADULTS
    MAYOR, HD
    DRAKE, S
    STAHMANN, J
    MUMFORD, DM
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1976, 126 (01) : 100 - 104
  • [37] The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer
    Theriault, R
    Jakesz, R
    Gnant, M
    Gralow, J
    BONE, 2004, 34 : S90 - S91
  • [38] The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer
    Therialt, R.
    Gnant, M.
    Gralow, J.
    EJC SUPPLEMENTS, 2004, 2 (03): : 77 - 77
  • [39] Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems
    Peschke, Katja
    Jakubowsky, Hannah
    Schaefer, Arlett
    Maurer, Carlo
    Lange, Sebastian
    Orben, Felix
    Bernad, Raquel
    Harder, Felix N.
    Eiber, Matthias
    Oellinger, Rupert
    Steiger, Katja
    Schlitter, Melissa
    Weichert, Wilko
    Mayr, Ulrich
    Phillip, Veit
    Schlag, Christoph
    Schmid, Roland M.
    Braren, Rickmer F.
    Kong, Bo
    Demir, Ihsan Ekin
    Friess, Helmut
    Rad, Roland
    Saur, Dieter
    Schneider, Gunter
    Reichert, Maximilian
    EMBO MOLECULAR MEDICINE, 2022, 14 (04)
  • [40] Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?
    Shanafelt, TD
    Loprinzi, C
    Marks, R
    Novotny, P
    Sloan, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1966 - 1974